<DOC>
	<DOCNO>NCT02834312</DOCNO>
	<brief_summary>This dose-finding study conduct select daily oral dose estetrol ( E4 ) treatment vasomotor symptom ( VMS ) post-menopausal woman .</brief_summary>
	<brief_title>E4Relief ( Response Estetrol Life Improvement MEnopausal-associated Hot Flushes )</brief_title>
	<detailed_description>Oestrogen therapy consistently effective treatment use US Europe menopausal VMS . Following safety issue report primary Women 's Health Initiative publication continue subject request treatment , challenge clinician identify low effective dose oestrogen alleviate menopausal symptom . In addition , challenge develop safe oestrogen currently use . For purpose , minimum effective dose ( MED ) E4 define treatment menopausal symptom . The present study intend evaluate change frequency severity moderate severe VMS order define MED . Subjects randomly allocate either treatment group ( 2.5 mg E4 , 5 mg E4 , 10 mg E4 , 15 mg E4 , placebo ) 1:1:1:1:1 ratio . All treatment ( E4 Placebo ) administer daily ( QD ) per o least 12 consecutive week last biological assessment ( Day 90 maximum ) perform .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>Women present least 7 moderate severe hot flushes/day least 50 moderate severe hot flushes/week week precede randomization . Body Mass Index ( BMI ) 18.0 35.0 kg/mÂ² , inclusive . Postmenopausal status . Intact uterus . Negative pregnancy test . Good physical mental health . Subject provide sign dated write informed consent admission study . Subject able understand comply protocol requirement , instruction , protocolstated restriction . Uterine disease medical condition associate increase endometrial thickness . Any history malignancy exception basal cell ( exclude within prior 2 year ) squamous cell ( exclude within prior one year ) carcinoma skin . Any clinically significant finding breast examination and/or mammography suspicious breast malignancy would require additional clinical testing rule breast cancer . Abnormal cervical Pap smear . Systolic blood pressure ( BP ) outside range 90 140 mmHg , diastolic BP outside range 60 90 mmHg , and/or heart rate outside range 40 100 bpm . Any clinically significant abnormality identify screen 12lead ECG . History venous arterial thromboembolic disease , history know coagulopathy abnormal coagulation factor . Diabetes mellitus poor glycaemic control . Dyslipoproteinaemia screen . Smoking &gt; 10 cigarettes/day . Presence history gallbladder disease , unless cholecystectomy perform . Systemic lupus erythematosus . Multiple sclerosis . Acute chronic liver disease . Acute chronic renal impairment . Uncontrolled thyroid disorder . Use oestrogen progestin contain drug ( ) . Use nonhormonal treatment reduce hot flush . History presence allergy intolerance component investigational product . History alcohol substance abuse dependence 12 month screen determined Investigator . Sponsor , CRO Investigator 's site personnel relatives directly affiliate study . Subjects know suspected history clinically significant systemic disease , unstable medical disorder , lifethreatening disease current malignancy would pose risk subject opinion Investigator . Participation another investigational drug clinical study within 1 month ( 30 day ) receive investigational drug within last 3 month ( 90 day ) prior study entry . Is judged Investigator unsuitable reason .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Estetrol</keyword>
	<keyword>Vasomotor symptom</keyword>
	<keyword>Menopause</keyword>
</DOC>